Acer Therapeutics Announces Appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer
Industry veteran with over 20 years of drug development experience to oversee advancement of Acer’s product pipeline Adrian Quartel, MD,...
Day: February 22, 2022
Albireo to Report Q4 and Year-End 2021 Financial Results on March 1
— Conference call and webcast to be held at 10:00 a.m. ET —BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Albireo...
Pennsylvania-Based Health System Signs New Contract for Streamline Health® eValuator™
Regional Provider Chooses Automated Coding Analysis for Inpatient and Outpatient Care to Improve Revenue Performance Atlanta, GA, Feb. 22, 2022...
Chinook Therapeutics Announces Upcoming Presentations at 4th Annual Chronic Kidney Disease Drug Development Summit
SEATTLE, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development...
Akoya to Report Fourth Quarter and Full Year 2021 Financial Results on March 14th, 2022 and Present at the Cowen Annual Health Care Conference on March 8th, 2022
MARLBOROUGH, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced...
Black Diamond Therapeutics Appoints Elizabeth Montgomery as Chief People Officer
CAMBRIDGE, Mass. and NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology...
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Tuesday, March 1, 2022
BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the...
Athenex Announces Appointment of Chief Financial Officer
BUFFALO, N.Y., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery,...
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast
NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and...
Aquestive Therapeutics to Report Fourth Quarter and Year End 2021 Financial Results and Recent Business Highlights on March 8 and Host Conference Call on March 9 at 8:00 a.m. ET
WARREN, N.J., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company improving and advancing medicines...
Neoleukin Therapeutics to Host 2021 Financial Results Conference Call and Webcast on March 1, 2022
SEATTLE, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to...
PROCEPT BioRobotics Corp. to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022
REDWOOD CITY, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on...
Morphic Presents Positive MORF-057 Data in Oral Presentation at ECCO 2022
New preclinical data expand understanding of α4β7-expressing immune cells and MORF-057 dose response Data support ongoing clinical development program in...
Supernus Receives Notice Assigning Early October 2022 PDUFA for SPN-830 Apomorphine Infusion Device NDA
ROCKVILLE, Md., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...
ImmixBio Initiates GMP Manufacturing of IMX-120, a Biologic for Inflammatory Bowel Disease
ImmixBio Initiates GMP Manufacturing of IMX-120, a Biologic for Inflammatory Bowel Disease Immix Biopharma, Inc. (NASDAQ:IMMX)IMX-120 utilizes proprietary, humanized antibody...
Triphase Accelerator Announces Positive Updated Phase 1 Data with TRPH-222 in Non-Hodgkin’s Lymphoma
High response rates: ORR of 54% and a CR rate of 38%Durable responses: ~25 months median duration of response Favourable...
CytomX Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field...
Alignment Healthcare to Participate in Two Upcoming Investor Conferences
ORANGE, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (“Alignment Healthcare” or the “Company”) (Nasdaq: ALHC), a tech-enabled...
Dyve Biosciences to Present at the Biocom California Global Life Science Partnering Conference
CAMARILLO, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal...
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
– ARCALYST® (rilonacept) net revenue of $18.7 million in Q4 2021 and $38.5 million in 2021 –– ARCALYST collaboration achieved profitability...
